PatientsVille.com Logo

HYPERTENSION and Celexa

PatientsVille

HYPERTENSION Symptoms and Causes

Blood pressure is the force of your blood pushing against the walls of your arteries. Each time your heart beats, it pumps blood into the arteries. Your blood pressure is highest when your heart beats, pumping the blood. This is called systolic pressure. When your heart is at rest, between beats, your blood pressure falls. This is called diastolic pressure.

Your blood pressure reading uses these two numbers. Usually the systolic number comes before or above the diastolic number. A reading of

  • 119/79 or lower is normal blood pressure
  • 140/90 or higher is high blood pressure
  • Between 120 and 139 for the top number, or between 80 and 89 for the bottom number is called preHypertension. PreHypertension means you may end up with high blood pressure, unless you take steps to prevent it.

High blood pressure usually has no symptoms, but it can cause serious problems such as stroke, heart failure, heart attack and kidney failure.

You can control high blood pressure through healthy lifestyle habits such as exercise and the DASH diet and taking medicines, if needed.

NIH: National Heart, Lung, and Blood Institute

Check out the latest treatments for HYPERTENSION

HYPERTENSION treatment research studies

Celexa clinical trials, surveys and public health registries


Find Drug Side Effect reports



Celexa Side Effects

Dizziness (134)
Nausea (131)
Suicidal Ideation (124)
Anxiety (122)
Completed Suicide (120)
Headache (120)
Depression (120)
Pain (111)
Insomnia (109)
Feeling Abnormal (102)
Vomiting (101)
Diarrhoea (98)
Fall (96)
Fatigue (91)
Loss Of Consciousness (89)
Tremor (89)
Dyspnoea (85)
Agitation (78)
Confusional State (76)
Aggression (69)
Asthenia (38)
Convulsion (34)
Suicide Attempt (33)
Condition Aggravated (32)
Abnormal Behaviour (32)
Weight Increased (31)
Somnolence (30)
Anger (30)
Pulmonary Embolism (28)
Malaise (28)
Chest Pain (28)
Crying (27)
Irritability (27)
Abdominal Pain Upper (25)
Abdominal Pain (25)
Constipation (25)
Overdose (25)
Serotonin Syndrome (25)
Paraesthesia (25)
Syncope (24)
Amnesia (24)
Hyperhidrosis (24)
Intentional Self-injury (22)
Hypertension (21)
Arthralgia (21)
Injury (20)
Palpitations (20)
Heart Rate Increased (20)
Blood Pressure Increased (20)
Rash (19)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

After being discharged from eER I saw in my file that the doppler impression shows mild tricuspid regurgitation and mild pulmonary hypertension =-O scared should I be worried

Can ratio-citalopram be taken long term with Lectopam 6 mg?

Celexa triggered my tourettes syndrome. Three weeks after starting this med, I started having motor and vocal tics. Do not advise anyone to take this drug. It sucks.

How long can one live with the diagnosis of pulmonary hypertension? I have seen 3 to 5 years but I have had it for well over 10.

I need to find out if Celexa is available in Ecuador as I will be living there for several months. Thanks.

I Took celexa for about 7 years im a 28 year old male. A couple months after getting off of the drug I have been twitching all over my body. Feet, legs,thighs,arms,stomach,hands,face,everywhere. I also have this feeling of a lump stuck in my throat.

It probably didn't trigger your TS. It was probably just supressing symptoms to a point where they were un noticable. Celexa is something they use to help alleviate the symptoms. so when you came off of it, they came back. They could have developed w

Have been taking Kliovance for approx 5 years. I am aged 55 years and have been diagnosed with hypertension. I have a sedentary lifestyle, a poor diet, and a stressful job. I have been getting a difference of opinion between 2 doctors. One says th

Have been taking Kliovance for approx 5 years. I am aged 55 years and have been diagnosed with hypertension. I have a sedentary lifestyle, a poor diet, and a stressful job. I have been getting a difference of opinion between 2 doctors. One says that

53 yrs.old, 125 lb. female,otherwise healthy and active person (non-smoker, good fitness level, active, eats healthy food, no underlying health issues)diagnosed with hypertension in Feb./08 Prescribed Marcardis Plus initially for the first 3 mos.

After being discharged from eER I saw in my file that the doppler impression shows mild tricuspid regurgitation and mild pulmonary hypertension =-O scared should I be worried

After taking several famous brands of hypertension meds. Calblock has exceeded expectations. The problem is that I cant find them available in the USA. Does anyone know of a source where they can be ordered online?

Although Karvezide controlled my hypertension, it leaves me with dry mouth and I find it difficult to sleep well during the nights, so my doctor switched me back to Karvea. After switching for 2 days, I already notice the increase in my blood pressu

Amlodpine is a dihydropyridine group Ca channel blocker usually prescribed to controll hypertension (Males) or prinz metal angina (Females) trade names Norvasac Quvasac ..... Ca channels are universally present in our b

As a 58 year old correction officer with hypertension and moderate TAA could restraining an inmate or fight endanger the aneurysm bursting?

BAD EFFECT. IS IT APPLICABLE IF YOU ARE HYPERTENSION?

Been on Istin 5mg for four years for Hypertension. Ankle swelling left leg mostly but some times right ankle also. Occasional feelings of anxiety. Feet and hands cold by times. Soreness in spinal column especially upper area. General feeling of out o

HYPERTENSION Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Induced Hypertension for Treatment of Delayed Cerebral Ischaemia After Aneurysmal Subarachnoid Haemorrhage
Conditions: Cerebral Ischemia;   Subarachnoid Hemorrhage
Intervention: Other: Induced Hypertension
Outcome Measures: The main outcome measurement will be the modified Rankin scale at 3 months after the SAH, compared between patients who were randomized to induced Hypertension and patients who were randomized to no induced Hypertension.;   Related to treatment failure: proportion of patients in the induced Hypertension group in which induced Hypertension did not give clinical improvement of symptoms of DCI within 24 hours;   Related to the functional condition: Case fatality 30 days after SAH;   Related to the functional condition, activities of daily living (ADL), three months after the SAH assessed with the Barthel Index.;   Related to the functional condition: quality of life, three months after the SAH, estimated with the Stroke Specific Quality of Life Scale (SSQoL-12-NL).;   Related to the functional condition: anxiety and depression, three months after the SAH, assessed with the Hospital Anxiety and Depression Scale (HADS).;   Related to the functional condition: cognitive functioning, three months after the SAH, evaluated by the Cognitive Failures Questionnaire (CFQ).;   Related to adverse effects: complications related to insertion of a central venous catheter or intra-arterial catheter (including local haemorrhage and pneumothorax).;   Related to adverse effects: intracranial complications related to induced Hypertension (such as exacerbation of cerebral oedema, hemorrhagic infarction and bleeding of an asymptomatic aneurysm).;   Related to adverse effects± • Systemic complications related to induced Hypertension (including cardiac rhythm disorders, low cardiac output state and cardiac ischemia).;   In selected centres: Related to the influence on cerebral haemodynamics: the difference in CBF, CBV, TTP and MTT between the intervention and the control groups 24-36 hours after the start of the study (i.e. CTP-2);   Related to the influence on cerebral haemodynamics: the difference in CBF, CBV, TTP and MTT between the perfusion CT-scan (at baseline, the moment of deterioration, i.e. CTP-1) and the second perfusion CT-scan (CTP-2) within the same patients.;   Direct medical costs of used health care resources and indirect, non-medical costs of lost productivity, will be compared between the two arms of the trial, twelve months after the SAH.
2 Recruiting Trans-pulmonary Biomarkers in Pulmonary Hypertension
Condition: Pulmonary Hypertension
Intervention:
Outcome Measures: Differences in Pulmonary Hypertension biomarkers in patients evaluated for Pulmonary Hypertension;   Vasodilator-induced changes in Pulmonary Vascular Resistance (PVR);   Vasodilator-induced changes in Pulmonary Hypertension biomarkers
3 Unknown  ABMSC Infusion Through Hepatic Artery in Portal Hypertension Surgery for the Treatment of Liver Cirrhosis
Conditions: Liver Cirrhosis;   Portal Hypertension;   Hepatic Decompensation;   Surgery
Interventions: Procedure: Autologous bone marrow stem cells infusion (ABMSCi) plus abdominal portal Hypertension surgery;   Procedure: open abdominal portal Hypertension surgery
Outcome Measures: Child-pugh score;   Incidence of complications;   Mortality;   blood test (hypersplenism);   liver volume calculated by CT;   Indocyanine green (ICG) retention (clearance);   blood biochemistry
4 Recruiting GAstric Bypass to Treat obEse Patients With steAdy Hypertension
Conditions: Systemic Hypertension;   Obesity
Intervention: Procedure: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Outcome Measures: reduction of Hypertension medication prescription;   reduction of Hypertension medication prescription .
5 Recruiting Registry for Pulmonary Hypertension in China
Conditions: Pulmonary Arterial Hypertension;   Chronic Thromboembolic Pulmonary Hypertension;   Death
Intervention:
Outcome Measure: Survival
6 Recruiting Randomized Clinical Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients.
Conditions: Hypertension, Pregnancy Induced;   Hydralazine Adverse Reaction;   Pre-eclampsia;   Pre-eclampsia Superimposed Pre-existing Hypertension
Interventions: Drug: Labetalol;   Drug: Hydralazine
Outcome Measures: Sever persistent Hypertension;   Efficacy (Reduction in blood pressure below thresholds).;   Maternal tachycardia;   Bradycardia;   Bronchospasm;   Maternal hypotension
7 Unknown  Development and Pilot-Testing of a Patient Self Management Approach for Hypertension Using Personal Electronic Health Records
Condition: Hypertension
Intervention: Other: myBP facilitated e-health self-management
Outcome Measures: Change in Hypertension knowledge, patient self-efficacy, and patient engagement in self management activities after 3 months, in the intervention group compared to the control group;   Changes in blood pressure and antihypertensive medications
8 Unknown  Simvastatin in Patients With Isolated Arterial Hypertension
Condition: Hypertension
Intervention:
Outcome Measure:
9 Unknown  Pharmacogenomics in Pulmonary Arterial Hypertension
Conditions: Pulmonary Arterial Hypertension;   Pulmonary Hypertension;   PAH WHO Group I
Interventions: Drug: Sitaxsentan;   Drug: Bosentan, Ambrisentan
Outcome Measures: 6 Minute Walk Test;   Hemodynamics - Right Heart Catheterization;   Borg;   Functional Class - FC;   Toxicities;   Time of Clinical Worsening;   Decline in WHO Functional Class
10 Recruiting Auto-immunity and Pulmonary Arterial Hypertension
Conditions: Pulmonary Arterial Hypertension;   HIV Infection;   Congenital Heart Defect;   Systemic Sclerosis;   Connective Tissue Disease
Interventions: Procedure: skin biopsy;   Other: Blood Sample
Outcome Measures: Immunological markers of prognosis interest in pulmonary arterial Hypertension (PAH);   Target antigens of autoantibodies;   Subpopulations of patients with PAH whose serum is able to induce the production of reactive oxygen species (ROS)
11 Recruiting Measuring Adherence to Control Hypertension
Condition: Hypertension
Intervention: Behavioral: Electronically-measuring adherence to antihypertensive medications
Outcome Measures: Appropriateness of clinician Hypertension management;   Appropriateness of Regimen intensification;   Appropriateness of Adherence counseling;   Appropriateness of Hypertension regimen simplification
12 Recruiting Study of Personalized Dietary Intervention for the Control of Essential Hypertension
Condition: Essential Hypertension
Interventions: Other: PCFA interventional dietary counselling;   Other: conventional DASH diet counselling
Outcome Measures: a statistically significant 12 mm Hg (or more) greater change of blood pressure in one group compared to the other;   resolution of Hypertension (normal blood pressure, no drugs required);   serious (disabling) adverse events attributable to Hypertension or its drug treatment
13 Recruiting A Case Control Study of the Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Diseases.
Conditions: Myeloproliferative Disease;   Pulmonary Hypertension
Intervention: Other: myeloproliferative disease
Outcome Measures: pulmonary Hypertension;   St George Respiratory Questionnaire
14 Recruiting Efficacy and Safety Study of Sodium Tanshinone IIA Sulfonate on Pulmonary Hypertension
Conditions: Pulmonary Hypertension;   Pulmonary Arterial Hypertension;   Cardiovascular Diseases;   Lung Diseases;   Tanshinone IIA Sulfonate
Interventions: Drug: 20 mg sildenafil citrate by mouth;   Drug: sodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth
Outcome Measures: mPAP by right heart catheterization;   WHO functional class of pulmonary Hypertension(PH);   Borg dyspnea score;   Minnesota living with heart failure questionnaire;   6-minute walk distance (6MWD);   Pulmonary vascular resistance(PVR) measured by right heart catheterization
15 Not yet recruiting Optical Coherence Tomography (OCT) in Hypertension & Chronic Kidney Disease (CKD)
Conditions: Health;   Hypertension;   Chronic Kidney Disease
Intervention:
Outcome Measures: Choroidal & retinal morphology;   Neuro-retinal metrics
16 Unknown  Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension
Conditions: Sarcoidosis;   Pulmonary Hypertension
Intervention: Drug: Ambrisentan
Outcome Measure: Change in 6 minute walk distance.
17 Recruiting A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn
Condition: Pulmonary Hypertension, Familial Persistent, of the Newborn
Interventions: Drug: placebo;   Drug: iv sildenafil
Outcome Measures: Time on inhaled nitric oxide treatment after initiation of iv study drug;   Treatment failure rate, defined as need for additional treatment targeting persistent pulmonary Hypertension of the newborn.;   Time to final weaning of mechanical ventilation for persistent pulmonary Hypertension of the newborn;   Time from initiation of study drug to treatment failure;   Change in oxygenation parameters at 6, 12, and 24 hours from baseline;   Sildenafil plasma concentrations and corresponding PK parameters;   Safety parameters: incidence and severity of adverse events and abnormal laboratory parameters
18 Recruiting Evaluation of Pulmonary Perfusion Heterogeneity and Compliance in Patients With Pulmonary Hypertension Using Positron Emission Tomography Imaging
Condition: Pulmonary Arterial Hypertension
Intervention: Other: CT imaging, functional PET imaging
Outcome Measures: Coefficient of variation of perfusion;   Vascular compliance;   Perfusion gradient
19 Recruiting Observational Study to Investigate Resistant Hypertension Prevalence in Korean General Hospitals
Condition: Hypertension
Intervention:
Outcome Measures: Prevalence of resistant Hypertension;   Analysis of correlation in patients with resistant Hypertension and patients with controlled Hypertension who received triple antihypertensive therapy in terms of demography, clinical characteristics and other factors
20 Unknown  Simvatstatin Used to Treat Pulmonary Hypertension
Condition: Hypertension, Pulmonary
Intervention: Drug: simvastatin
Outcome Measures: the simvastatin can alleviate pulmonary Hypertension;   pulmonary pressure;   simvastatin can highten the perioperative and long term survaval rate and the living quality